Who
Yu-Hsin Lin
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Belite Bio.
In numbers
- Trades disclosed
- 54
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $41.6M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 31 Mar 2026
- Last trade
- 8 Sep 2026
- Last filed
- 9 Sep 2026
Companies traded
Activity over time
1 Apr – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Sep 2026filed 9 Sep 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $466K2,400 at $194.33 | filing |
| 8 Sep 2026filed 9 Sep 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $1.2M6,090 at $195.62 | filing |
| 8 Sep 2026filed 9 Sep 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $1.2M6,058 at $196.54 | filing |
| 8 Sep 2026filed 9 Sep 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $1.7M8,752 at $197.36 | filing |
| 8 Sep 2026filed 9 Sep 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $535K2,700 at $198.09 | filing |
| 8 Sep 2026filed 9 Sep 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $466K2,400 at $194.33 | filing |
| 8 Sep 2026filed 9 Sep 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $1.2M6,090 at $195.62 | filing |
| 8 Sep 2026filed 9 Sep 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $1.2M6,058 at $196.54 | filing |
| 8 Sep 2026filed 9 Sep 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $1.7M8,752 at $197.36 | filing |
| 8 Sep 2026filed 9 Sep 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $535K2,700 at $198.09 | filing |
| 4 Sep 2026filed 9 Sep 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $475K2,635 at $180.29 | filing |
| 4 Sep 2026filed 9 Sep 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $1.7M8,955 at $189.34 | filing |
| 4 Sep 2026filed 9 Sep 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $114K600 at $190.39 | filing |
| 4 Sep 2026filed 9 Sep 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $2.1M11,080 at $191.15 | filing |
| 4 Sep 2026filed 9 Sep 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $810K4,209 at $192.54 | filing |
| 4 Sep 2026filed 9 Sep 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $1.6M8,111 at $193.13 | filing |
| 4 Sep 2026filed 9 Sep 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $469K2,587 at $181.24 | filing |
| 4 Sep 2026filed 9 Sep 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $623K3,413 at $182.50 | filing |
| 4 Sep 2026filed 9 Sep 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $908K4,955 at $183.30 | filing |
| 4 Sep 2026filed 9 Sep 2026 | BLTE Belite BioBiotechnology | SEC FORM 4 Sold | $1.2M6,252 at $184.52 | filing |
News
No headline names them, or the companies they trade most, lately.